



FORM PTO-1595 (Rev. 6-93) OMB No. 0651-0011 (exp. 10-04)		RE 01-08-2003  102331812		SHEET U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office	
To the Honorable Commissioner of Patents and Trademarks		ched original documents or copy thereof.			
1. Name of conveying party(ies): Thomas D. Wetsch Additional name(s) of conveying party(ies) attached? () Yes (X) No		2. Name and address of receiving party(ies) Name: Pinnacle Design Technologies, Inc. Internal Address: Street Address: 1503 Keim Court, City: <u>St. Charles</u> State: <u>IL</u> ZIP: <u>60174</u> Additional name(s) & address(es) attached: () Yes (X) No			
3. Nature of conveyance: (X) Assignment () Merger () Security Agreement () Change of Name () Other _____ Execution Date: December 12, 2002		4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: A. Patent Application No.(s) <u>09/885,770</u> B. Patent No.(s) _____ Additional numbers attached? () Yes (X) No.			
5. Name and address of party to whom correspondence concerning document should be mailed: Name: Lawrence J. Crain, Esq. Greer, Burns & Crain, Ltd. Internal Address: 300 South Wacker Drive 25th Floor Chicago, Illinois 60606 Street Address: _____ City: _____ State: _____ ZIP: _____ Additional name(s) & address(es) attached: () Yes (X) No		6. Total number of applications and patents involved: 1 7. Total fee (37 CFR 3.41) \$ 40.00 (X) Enclosed (X) Authorized to be charged to deposit account only in the event proper payment is not enclosed. 8. Deposit account number: 07-2069 (Attach duplicate copy of this page if paying by deposit account)			
DO NOT USE THIS SPACE					
9. Statement and signature. <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i> <div style="display: flex; justify-content: space-between;"> <div style="width: 30%;"> <u>Arik B. Ranson</u> Name of Person Signing </div> <div style="width: 30%; text-align: center;">  Signature </div> <div style="width: 30%; text-align: right;"> <u>December 20, 2002</u> Date </div> </div> <div style="text-align: right; margin-top: 10px;"> Total number of pages including cover sheet, attachments, and document: 3 </div>					
2317.65430					

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

01/07/2003 GTOM11 00000223 09885770
 01 FC:8021 40.00 0P

Patent and Trademark Assignments
 Created in Microsoft Word
 File Name: J:\rr\readdata\projects\ptas\barcodes\PTAS Document Separator.doc

PATENT
REEL: 013624 FRAME: 0286

VPI98-09 PCT

CONFIRMATORY ASSIGNMENT

WHEREAS, on June 8, 1999, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of the Commonwealth of Massachusetts and having an office and place of business at 130 Waverly Street, Cambridge, Massachusetts (U.S.A.) 02139, obtained by assignment from Francesco Salituro, Guy Bemis, and John Cochran all of their right, title, and interest in the inventions and discoveries disclosed in an International Patent Application, filed under the Patent Cooperation Treaty in the United States Receiving Office (RO/US), entitled: "INHIBITORS OF p38", claiming priority from United States Provisional Patent Application No. 60/089,147, filed June 12, 1998, and designating Albania (AL), Armenia (AM), Australia (AU), Austria (AT), Azerbaijan (AZ), Barbados (BB), Belarus (BY), Belgium (BE), Benin (BJ), Bosnia and Herzegovina (BA), Brazil (BR), Bulgaria (BG), Burkina Faso (BF), Cameroon (CM), Canada (CA), Central African Republic (CF), Chad (TD), China (CN), Congo (CG), Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY), Czech Republic (CZ), Democratic People's Republic of Korea (KP), Denmark (DK), Estonia (EE), Finland (FI), France (FR), Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana (GH), Grenada (GD), Greece (GR), Guinea (GN), Guinea-Bissau (GW), Hungary (HU), Iceland (IS), India (IN), Indonesia (ID), Ireland (IE), Israel (IL), Italy (IT), Japan (JP), Kazakstan (KZ), Kenya (KE), Kyrgyzstan (KG), Latvia (LV), Lesotho (LS), Liberia (LR), Liechtenstein (LI), Lithuania (LT), Luxembourg (LU), Madagascar (MG), former Yugoslav Republic of Macedonia (MK), Malawi (MW), Mali (ML), Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN), Netherlands (NL), New Zealand (NZ), Niger (NE), Norway (NO), Poland (PL), Portugal (PT), Republic of Korea (KR),

page 1 of 5

Republic of Moldova (MD), Romania (RO), Russian Federation
(RU), Saint Lucia (LC), Senegal (SN), Sierra Leone (SL),
Singapore (SG), Slovakia (SK), Slovenia (SI), South Africa
(ZA), Spain (ES), Sri Lanka (LK), Sudan (SD), Swaziland
(SZ), Sweden (SE), Switzerland (CH), Tajikistan (TJ),
Togo (TG), Trinidad and Tobago (TT), Turkey (TR),
Turkmenistan (TM), Uganda (UG), Ukraine (UA), United Arab
Emirates (AE), United Kingdom (GB), United States of
America (US), Uzbekistan (UZ), Viet Nam (VN), Yugoslavia
(YU), and Zimbabwe (ZW), identified as International

Patent Application PCT/US99/12951, filed June 11, 1999;

WHEREAS, VERTEX PHARMACEUTICALS INCORPORATED,
Francesco Salituro, Guy Bemis, and John Cochran are
desirous of confirming the transfer of their right, title,
and interest in and to said International Patent
Application PCT/US99/12951 to said VERTEX PHARMACEUTICALS
INCORPORATED, its successors, assigns and legal
representatives;

NOW, THEREFORE, be it known that in
consideration already received by us, we, Francesco
Salituro, Guy Bemis, and John Cochran do hereby confirm
that we have sold, assigned and transferred to said VERTEX
PHARMACEUTICALS INCORPORATED, its successors, assigns and
legal representatives, as of June 8, 1999 all right, title
and interest in and to said International Patent
Application PCT/US99/12951 and any and all of the
International patent applications in respect of
contracting states, including any continuations and
divisions thereof, and any substitute applications
therefor, and including the right to claim priority under
the International Convention based on said patent
application, and any patent which has issued or may issue
thereon, and any reissues of the same; and all right,
title and interest in and to every patent application
filed or to be filed on said invention in any other

country, including renewals, revivals, continuations and divisions thereof, and any substitute applications therefor, and any and all patents which may issue thereon, and any reissues and extensions of the same; and we hereby confirm that we authorize and request competent authorities to grant and issue any and all patents on said invention to said VERTEX PHARMACEUTICALS INCORPORATED, its successors, assigns, and legal representatives, as the assignee of the entire interest therein; and we further hereby confirm that we agree to execute upon request of said VERTEX PHARMACEUTICALS INCORPORATED, its successors, assigns, and legal representatives, such additional documents, if any, as are necessary and proper to secure patent protection on said invention throughout all countries of the world, and to otherwise give full effect to and perfect the rights of the assignee under this Assignment.

ASSIGNORS:

By: Francesco Salituro
Francesco Salituro

12-20-02
Date

By: Guy Bemis
Guy Bemis

12/20/02
Date

By: John Cochran
John Cochran

12/20/02
Date

Middlesex; ss

On this 20th day of December,
2002, (1) Francesco Salituro personally appeared before
me, a Notary Public in and for the Commonwealth of
Massachusetts, and duly acknowledged the executed
Assignment on behalf of the Assignee.

Michelle O. Rosen

Notary Public
MICHELLE O. ROSEN, Notary Public
My Commission Expires June 19, 2003

Middlesex; ss

On this 20th day of December,
2002, (2) Guy Bemis personally appeared before me, a
Notary Public in and for the Commonwealth of
Massachusetts, and duly acknowledged the executed
Assignment on behalf of the Assignee.

Michelle O. Rosen

Notary Public

Middlesex; ss

MICHELLE O. ROSEN, Notary Public
My Commission Expires June 19, 2003

On this 20th day of December,
2002, (3) John Cochran personally appeared before me, a
Notary Public in and for the Commonwealth of
Massachusetts, and duly acknowledged the executed
Assignment on behalf of the Assignee.


Michelle O. Rosen

Notary Public

MICHELLE O. ROSEN, Notary Public
My Commission Expires June 19, 2003

ACKNOWLEDGMENT OF ASSIGNEE:

VERTEX PHARMACEUTICALS INCORPORATED

By: 

Andrew S. Marks

Chief Patent Counsel

Middlesex; ss

On this 28th day of December,

2002, Andrew S. Marks personally appeared before me, a
Notary Public in and for the Commonwealth of
Massachusetts, and duly acknowledged the executed
Assignment on behalf of the Assignee.



Notary Public

MICHELLE O. ROSEN, Notary Public
My Commission Expires June 19, 2003

PCT
ASSIGNMENT

I/We,

- (1) Francesco Salituro,
(2) Guy Bemis, and
(3) John Cochran,

residing, respectively, at

- (1) 25 Baker Drive
Marlboro, Massachusetts 01752 (U.S.A.),
(2) 256 Appleton Street
Arlington, Massachusetts 02476 (U.S.A.), and
(3) 700 Princeton Boulevard, Number 18
Lowell, Massachusetts 01851 (U.S.A.),

for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to, and do hereby assign, sell and transfer to VERTEX PHARMACEUTICALS INCORPORATED a corporation organized and existing under the laws of the COMMONWEALTH OF MASSACHUSETTS and having an office and a place of business at 130 WAVERLY STREET, CAMBRIDGE, MASSACHUSETTS 02139-4242, its successors and assigns: (1) the entire right, title and interest in all countries throughout the world in and to any and all my/our inventions and discoveries disclosed in my/our International Patent Application, filed under the Patent Cooperation Treaty in the United States Receiving Office (RO/US), entitled:

"INHIBITORS OF p38", and designating Albania (AL), Armenia (AM), Australia (AU), Austria (AT), Azerbaijan (AZ), Barbados (BB), Belarus (BY), Belgium (BE), Benin (BJ), Bosnia and Herzegovina (BA), Brazil (BR), Bulgaria (BG), Burkina Faso (BF), Cameroon (CM), Canada (CA), Central

African Republic (CF), Chad (TD), China (CN), Congo (CG),
Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY),
Czech Republic (CZ), Democratic People's Republic of Korea
(KP), Denmark (DK), Estonia (EE), Finland (FI), France (FR),
Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana
(GH), Grenada (GD), Greece (GR), Guinea (GN), Guinea-Bissau
(GW), Hungary (HU), Iceland (IS), India (IN), Indonesia
(ID), Ireland (IE), Israel (IL), Italy (IT), Japan (JP),
Kazakstan (KZ), Kenya (KE), Kyrgyzstan (KG), Latvia (LV),
Lesotho (LS), Liberia (LR), Liechtenstein (LI), Lithuania
(LT), Luxembourg (LU), Madagascar (MG), former Yugoslav
Republic of Macedonia (MK), Malawi (MW), Mali (ML),
Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN),
Netherlands (NL), New Zealand (NZ), Niger (NE), Norway (NO),
Poland (PL), Portugal (PT), Republic of Korea (KR), Republic
of Moldova (MD), Romania (RO), Russian Federation (RU),
Saint Lucia (LC), Senegal (SN), Sierra Leone (SL), Singapore
(SG), Slovakia (SK), Slovenia (SI), South Africa (ZA), Spain
(ES), Sri Lanka (LK), Sudan (SD), Swaziland (SZ), Sweden
(SE), Switzerland (CH), Tajikistan (TJ), Togo (TG), Trinidad
and Tobago (TT), Turkey (TR), Turkmenistan (TM), Uganda
(UG), Ukraine (UA), United Arab Emirates (AE), United
Kingdom (GB), United States of America (US), Uzbekistan
(UZ), Viet Nam (VN), Yugoslavia (YU), and Zimbabwe (ZW),
[subsequently identified as International Patent Application
_____, filed _____*], including any
renewals, revivals, reissues, reexaminations, extensions,
continuations and divisions thereof, and any substitute
applications therefor; (2) the full and complete right to
file patent applications in the name of VERTEX
PHARMACEUTICALS INCORPORATED, its designee, or in my/our
names at VERTEX PHARMACEUTICALS INCORPORATED, or its

* I/We hereby authorize Vertex Pharmaceuticals Incorporated and its
representatives to insert in this instrument the International Patent
Application number and the filing date of said application when
Vertex Pharmaceuticals Incorporated is officially notified thereof.

designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent which may issue on the aforesaid inventions, discoveries and applications in any country of the world and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the following priority application(s):

<u>60/089,147</u>	<u>U.S.A.</u>	<u>June 12, 1998</u>
application no.	country	filing date

and all rights of priority in any country of the world deriving from the above-identified International Patent Application.

I/We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in any country throughout the world to VERTEX PHARMACEUTICALS INCORPORATED as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by me/us had this assignment, sale and transfer not been made.

I/We agree, at any time, upon the request of VERTEX PHARMACEUTICALS INCORPORATED to execute and to deliver to VERTEX PHARMACEUTICALS INCORPORATED any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

page 3 of 6

06/03/99 05:31 PM
03602.015 - [NY]561295.1


PATENT
REEL: 013624 FRAME: 0294

I/We further agree, at any time, upon request of VERTEX PHARMACEUTICALS INCORPORATED to execute and to deliver to VERTEX PHARMACEUTICALS INCORPORATED such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect any and all rights of VERTEX PHARMACEUTICALS INCORPORATED under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNORS:

 (1)

Francesco Salituro

 (2)

Guy Bemis

 (3)

John Cochran

On this ____ day of _____, 1999,
Francesco Salituro (1) personally appeared before me, a
Notary Public in and for the Commonwealth of Massachusetts,
and executed the foregoing Assignment and duly acknowledged
to me that such Assignment was executed for the uses and
purposes therein expressed.

Notary Public

page 4 of 6

06/03/99 05:31 PM
03602.015 - [NY]561295.1

PATENT
REEL: 013624 FRAME: 0295

ACKNOWLEDGEMENT OF ASSIGNEE:

By: _____

Joshua S. Boger
President and Chief Executive Officer

On this 8th day of June, 1999,
Joshua S. Boger personally appeared before me, a Notary
Public in and for the Commonwealth of Massachusetts, and
duly acknowledged the executed Assignment on behalf of the
Assignee.

Phyllis A. Tobey
Notary Public

PHYLLIS A. TOBEY
Notary Public
My Commission Expires May 8 2001

page 6 of 6

06/03/99 05:31 PM
03602.015 - [NY]561295.1

RECORDED: 01/03/2003

PATENT
REEL: 013624 FRAME: 0296